Americans ditch pills for protein and fiber as dietary guidelines spark a food revolution
Americans ditch pills for protein and fiber as dietary guidelines spark a food revolution
Americans ditch pills for protein and fiber as dietary guidelines spark a food revolution
A growing number of Americans now favour food over prescription drugs to maintain their health. According to recent surveys, 76% prefer dietary solutions for wellness. This shift comes as new US dietary guidelines spark debate by promoting protein-rich foods, including some controversial choices like saturated fats.
The updated dietary guidelines place protein sources—meats, eggs, and whole dairy—at the centre of recommended diets. This move mirrors rising consumer demand, with protein-rich food sales climbing from $19.9 billion in 2020 to $24.5 billion in 2024. Growth has been steady at around 5.3% annually, driven by both traditional and plant-based fiber sources.
Plant-based fibers have seen a notable rise, increasing their market share from 2.5% to 4.1% over the same period. Data from Nielsen and SPINS confirms this trend, showing a clear shift in buying habits. Major food companies have taken notice, with brands like PepsiCo, Kraft-Heinz, and Kellogg reformulating products to meet demand for healthier choices.
The guidelines have reignited discussions around the MAHA debate—meat, alternative meats, and highly processed foods. While some experts question the emphasis on saturated fats, the food industry is already adapting. Healthy food categories now lead sales growth across most grocery sections, reflecting a broader change in consumer priorities.
The new guidelines are likely to shape future food trends as businesses adjust to health-conscious buyers. With over half of shoppers now prioritising wellness in their food choices, the market for protein-rich and nutritious fiber options will continue expanding. Companies that align with these preferences are expected to see the strongest growth in the coming years.
Anavex stock plummets 50% after Alzheimer's drug faces EU regulatory rejection
A once-promising Alzheimer's treatment hits a wall in Europe. Can Anavex recover from this regulatory blow—or is this the end of blarcamesine's potential?
The pacifier's turbulent history: from ancient clay to modern medical battles
From toxic lead-dyed rubber to orthodontic breakthroughs, this tiny object has divided doctors and parents for generations. The fight isn't over yet.
Baxter's bold restructuring spins off BioPharma to fuel core growth by 2027
A second major split in six years signals Baxter's bet on high-growth markets. Will this unlock value for investors and patients alike?
Gossamer Bio's seralutinib fails critical Phase 3 trial, sending stock into freefall
A failed trial leaves Gossamer Bio's future hanging by a thread. With shares near collapse, all eyes turn to the FDA for a lifeline.